Ceftazidime/Avibactam and Other Commonly Used Antibiotics Activity Against Enterobacterales and Pseudomonas aeruginosa Isolated in Poland in 2015–2019

Abstract

Patrycja Zalas-Więcek,1 Małgorzata Prażyńska,1 Łukasz Pojnar,2 Anna Pałka,2 Dorota Żabicka,3 Monika Orczykowska-Kotyna,3 Aleksandra Polak,3 Barbara Możejko-Pastewka,4 Ewa Anna Głowacka,4 Izabela Pieniążek,5 Małgorzata Pawlik,5 Maciej Grys,5 Monika Bogiel4 1Department of Microbiology, Ludwik Rydygier Collegium Medicum; Department of Clinical Microbiology, University Hospital No. 1, Bydgoszcz, Poland; 2Department of Microbiology, University Hospital, Cracow, Poland; 3Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Warsaw, Poland; 4Pfizer Polska Sp. z o.o., Warsaw, Poland; 5Arcana Institute, a Certara Company, Cracow, PolandCorrespondence: Monika Bogiel, Pfizer Polska sp. z o.o., Żwirki i Wigury 16B, Warszawa, 02-092, Poland, Tel [phone], Fax [phone], Email [email protected]: Infections caused by resistant Gram-negative bacteria are becoming increasingly common and now pose a serious public health threat worldwide, because they are difficult to treat due to few treatment options and they are associated with high morbidity and mortality. The combination of ceftazidime with the beta-lactamase inhibitor avibactam – seems to be the right choice in this situation. The aim of the study was to evaluate the activity of ceftazidime/avibactam and other commonly used antibiotics against Enterobacterales and Pseudomonas aeruginosa strains isolated within last years in Poland.Patients and Methods: This study analyzed the antibiotic susceptibility of 1607 Enterobacterales isolates and 543 nonfermenting P. aeruginosa strains collected between 2015 and 2019 in 4 medical laboratories participating in the ATLAS (Antimicrobial Testing Leadership And Surveillance) program in Poland. Unduplicated clinically significant Enterobacterales and P. aeruginosa strains were collected from patients with respiratory, skin and musculoskeletal, genitourinary, abdominal, bloodstream or other infections (ear, eye).Results: The ceftazidime/avibactam combination demonstrates the highest activity against Enterobacterales (98.9%), in both adults and children, including strains presenting MDR (multidrug-resistant) (97.5%) and ESBL (extended spectrum β-lactamase) (96.3%) phenotypes. The activity of ceftazidime/avibactam increased to 100% when only MBL (metallo-β-lactamase)-negative subset of Enterobacterales was considered. This combination also achieved the second highest activity result (89.3%) after colistin in P. aeruginosa, including isolates of MDR (65.9%) and carbapenem-resistant (CR) phenotypes (54.8%). When MBL-positive isolates were excluded, susceptibility rate of P. aeruginosa increased to 94.7%. It is worth to note that susceptibility of the examined P. aeruginosa strains to ceftazidime/avibactam was very high in children (93.3%), especially in a pediatric intensive care unit (94.2%).Conclusion: Enterobacterales and P. aeruginosa included in this analysis presented high susceptibility rates to ceftazidime/avibactam. Ceftazidime/avibactam showed the highest activity against Enterobacterales strains among all antibiotics studied, both for the total population as well as for MDR phenotype and ESBL phenotype. Ceftazidime/avibactam also achieved the second highest activity result against P. aeruginosa strains (including MDR and CR phenotypes). These results are much higher when excluding MBL-positive isolates that exhibit intrinsic resistance to ceftazidime/avibactam.Keywords: ceftazidime/avibactam, drug resistance, Gram-negative rods, MDR, ESBL, carbapenem resistance

Keywords

• ceftazidime/avibactam
• drug resistance
• gram-negative rods
• mdr
• esbl
• carbapenem resistance